KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Retained Earnings (2018 - 2025)

Castle Biosciences (CSTL) has disclosed Retained Earnings for 8 consecutive years, with -$224.3 million as the latest value for Q4 2025.

  • Quarterly Retained Earnings fell 12.07% to -$224.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$224.3 million through Dec 2025, down 12.07% year-over-year, with the annual reading at -$224.3 million for FY2025, 12.07% down from the prior year.
  • Retained Earnings hit -$224.3 million in Q4 2025 for Castle Biosciences, down from $240000.0 in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $240000.0 in Q3 2025 to a low of -$226.0 million in Q1 2025.
  • Historically, Retained Earnings has averaged -$90.9 million across 5 years, with a median of -$75.6 million in 2021.
  • Biggest five-year swings in Retained Earnings: surged 135.7% in 2023 and later tumbled 295252.11% in 2024.
  • Year by year, Retained Earnings stood at -$87.4 million in 2021, then soared by 99.56% to -$381000.0 in 2022, then soared by 135.7% to $136000.0 in 2023, then crashed by 147251.47% to -$200.1 million in 2024, then decreased by 12.07% to -$224.3 million in 2025.
  • Business Quant data shows Retained Earnings for CSTL at -$224.3 million in Q4 2025, $240000.0 in Q3 2025, and $39000.0 in Q2 2025.